Drug regulators in Germany and France have ordered doctors to stop prescribing the type 2 diabetes drug pioglitazone (Actos) following a French study suggesting a heightened risk of bladder cancer.

(HealthDay News) — Despite smaller, prior studies suggesting that pioglitazone might raise users’ risk of bladder cancer, a large new study finds no statistically significant association. The research ...

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. A national third party payor class action related to Actos and alleged concealment of ...

LOS ANGELES (Reuters) - The U.S. Food and Drug Administration said on Friday its has begun a safety review of diabetes drug Actos after receiving early results from a long-term study designed to ...

Actos pioglitazone is a once-daily mere medication for people with adverse 2 diabetes. As specified above, Actos has been linked to a significantly cost of actos excretion of bladder cancer in some ...